Orphan drugs are considered to provide additional benefit by law, as long as sales within 12 months stay below a turnover limit of €30 mio (until 2022: €50 mio) xx different products comprising xx resolutions fall into this category. The G-BA only decides on the extent of this additional benefit. Therefore, orphan drugs received the most positive assessment so far from the G-BA: xx% of the patient subpopulations were granted a major additional benefit, xx% a considerable, xx% a minor and xx% a not quantifiable additional benefit. No additional benefit was identified in xx% of the patient population.